| Regimen Name |
Indication |
|
Bevacizumab 10 mg/kg –14 days
Regimen
|
00212c
In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.
|
|
Bevacizumab 15 mg/kg – 21 days
Regimen
|
00215e
In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.
|
|
Capecitabine Monotherapy
Regimen
|
00216a
Treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen of for whom further anthracycline therapy is not indicated.
00216b*
First line treatment of metastatic breast cancer or locally advanced breast cancer in a patient for whom anthracyclines and taxanes are contraindicated, or where the side effect profile and/or treatment delivery concerns would favour initial use of capecitabine.
|
|
Cyclophosphamide (oral) Methotrexate and 5-Fluorouracil (CMF) Therapy
Regimen
|
00377b
Metastatic breast carcinoma.
|
|
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) Therapy 21 day
Regimen
|
00381b
Metastatic breast carcinoma.
|
|
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) Therapy 28 day
Regimen
|
00378b
Metastatic breast carcinoma.
|
|
DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle
Regimen
|
00203h
Treatment of advanced breast cancer
|
|
DOCEtaxel Monotherapy 100mg/m2 - 21 day cycle
Regimen
|
00202a
DOCEtaxel monotherapy is indicated for the treatment of
patients with locally advanced or metastatic breast cancer.
|
|
DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy– 21 day cycle
Regimen
|
00423a
Treatment of Locally Advanced or Metastatic Breast Carcinoma
|
|
epiRUBicin 75 + Cyclophosphamide (EC75) Therapy
Regimen
|
00263a
Metastatic breast carcinoma.
|
|
eriBULin Monotherapy
Regimen
|
00228a
Treatment of locally advanced or metastatic breast cancer which has progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
|
|
Everolimus and Exemestane Therapy
Regimen
|
00322a
Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
|
|
Exemestane Monotherapy
Regimen
|
00376c
Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.
|
|
5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy
Regimen
|
00269a
Metastatic breast carcinoma
|
|
Lapatinib and Capecitabine
Regimen
|
0217a
Treatment of adult patients with breast cancer, whose tumours overexpress HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.
|
|
Letrozole Monotherapy
Regimen
|
00371c
Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.
|
|
PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day
Regimen
|
00621b
Treatment of metastatic breast carcinoma (mBC) in patients who have either failed or are not candidates for standard, anthracycline-containing therapy.
|
|
Nab-PACLitaxel (Abraxane®) Monotherapy – 21 day cycle
Regimen
|
00230a
Treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.
|
|
Palbociclib Therapy-28day
Regimen
|
00414a
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor
00414b
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy
|
|
Pegylated Liposomal DOXOrubicin 50mg/m2(CAELYX) ® 28 days Regimen
Regimen
|
00205a
Monotherapy for patients with metastatic breast cancer.
|
|
Pertuzumab and Trastuzumab and DOCEtaxel Therapy-21 day cycle
Regimen
|
00204a
Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti HER2 therapy or chemotherapy for their metastatic disease.
|
|
Pertuzumab Trastuzumab and weekly PACLitaxelTherapy-21 day cycle
Regimen
|
00507a
Pertuzumab is indicated in combination with trastuzumab and PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel.
|
|
Pertuzumab Trastuzumab and VinORELBine
Regimen
|
00526a
Pertuzumab in combination with trastuzumab and VinORELBine for the treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy
|
|
Ribociclib Therapy-28 days
Regimen
|
00525a
Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.
00525b
Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy.
In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
|
|
Trastuzumab (IV) Monotherapy - 7 days
Regimen
|
00201a
The treatment of patients with HER2 positive metastatic breast cancer (MBC).
|
|
Trastuzumab Subcutaneous_21 days - Metastatic Breast Carcinoma
Regimen
|
HER2 positive metastatic breast cancer (MBC)
00272a
As monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.
00272b
In combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.
00272c
In combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
00272d
In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.
|
|
Trastuzumab Emtansine (Kadcyla®)-21 days
Regimen
|
00206a
Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
Patients should have either:
- Received prior therapy for locally advanced or metastatic disease, or
- Developed disease recurrence during or within six months of completing adjuvant therapy.
|
